MRNA SEC Filing News — Moderna, Inc.

Latest SEC filings for Moderna, Inc. (MRNA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-30.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseas…
Sector: Healthcare Industry: Biotechnology Market Cap: $78.7B CIK: 1682852
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
11
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for MRNA currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
MRNA Filing Activity Snapshot 2026-07-31 — 2026-09-30
Insider Transactions (Form 4)
0 buys vs 4 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$28.96M
Bancel Stephane · 2026-08-05
499,246 shares · Form 144
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Moderna, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 7 option exercise and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Option exercise ×7
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market sale ×4
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-09-16

MRNA insider Hoge Stephen (President) sold 80,575 shares (~$11.69M)

Hoge Stephen, listed as President at Moderna, Inc., reported an open-market sale of 80,575 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 76,453 $12.21 $933.5K
S Open-market sale 40,294 $144.13 $5.81M
M Option exercise 76,452 $12.21 $933.5K
S Open-market sale 40,281 $146.07 $5.88M
M Option exercise derivative · Stock Option (Right to Buy) 76,453 — —
M Option exercise derivative · Stock Option (Right to Buy) 76,452 — —
Filing: Form 4 (Insider Transaction) Insider: Hoge Stephen (President) Shares: 80,575 Est. Value: $11.69M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-14

MRNA insider Mock James M (Chief Financial Officer) sold 34,836 shares (~$4.69M)

Mock James M, listed as Chief Financial Officer at Moderna, Inc., reported an open-market sale of 34,836 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 19,836 $30.96 $614.1K
S Open-market sale 19,836 $134.49 $2.67M
S Open-market sale 15,000 $134.49 $2.02M
M Option exercise derivative · Stock Option (Right to Buy) 19,836 — —
Filing: Form 4 (Insider Transaction) Insider: Mock James M (Chief Financial Officer) Shares: 34,836 Est. Value: $4.69M
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-08

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 11,797 — —
F Tax withholding on vested shares 5,704 $148.87 $849.2K
M Option exercise derivative · Restricted Stock Units 11,797 — —
Filing: Form 4 (Insider Transaction) Insider: Mock James M (Chief Financial Officer) Shares: 17,501
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-08

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 11,797 — —
F Tax withholding on vested shares 5,704 $148.87 $849.2K
M Option exercise derivative · Restricted Stock Units 11,797 — —
Filing: Form 4 (Insider Transaction) Insider: Klinger Shannon Thyme (Chief Legal Officer) Shares: 17,501
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

MRNA insider Klinger Shannon Thyme (Chief Legal Officer) sold 3,471 shares (~$485.8K)

Klinger Shannon Thyme, listed as Chief Legal Officer at Moderna, Inc., reported an open-market sale of 3,471 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 3,471 $30.96 $107.5K
S Open-market sale 3,471 $139.95 $485.8K
M Option exercise 2,166 — —
F Tax withholding on vested shares 1,048 $140.34 $147.1K
M Option exercise derivative · Stock Option (Right to Buy) 3,471 — —
M Option exercise derivative · Restricted Stock Units 2,166 — —
Filing: Form 4 (Insider Transaction) Insider: Klinger Shannon Thyme (Chief Legal Officer) Shares: 3,471 Est. Value: $485.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-03

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,475 — —
F Tax withholding on vested shares 1,197 $140.34 $168.0K
M Option exercise derivative · Restricted Stock Units 2,475 — —
Filing: Form 4 (Insider Transaction) Insider: Mock James M (Chief Financial Officer) Shares: 3,672
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-03

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,283 — —
F Tax withholding on vested shares 4,489 $140.34 $630.0K
M Option exercise derivative · Restricted Stock Units 9,283 — —
Filing: Form 4 (Insider Transaction) Insider: Hoge Stephen (President) Shares: 13,772
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-31

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,437 — —
F Tax withholding on vested shares 695 $149.66 $104.0K
M Option exercise 611 — —
F Tax withholding on vested shares 296 $142.77 $42.3K
M Option exercise derivative · Restricted Stock Units 1,437 — —
M Option exercise derivative · Restricted Stock Units 611 — —
Filing: Form 4 (Insider Transaction) Insider: Hoge Stephen (President) Shares: 3,039
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-31

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 774 — —
F Tax withholding on vested shares 375 $149.66 $56.1K
M Option exercise 329 — —
F Tax withholding on vested shares 160 $142.77 $22.8K
M Option exercise derivative · Restricted Stock Units 774 — —
M Option exercise derivative · Restricted Stock Units 329 — —
Filing: Form 4 (Insider Transaction) Insider: Klinger Shannon Thyme (Chief Legal Officer) Shares: 1,638
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-31

MRNA insider Form 4 filed for equity award, exercise, or tax withholding

Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 774 — —
F Tax withholding on vested shares 375 $149.66 $56.1K
M Option exercise 329 — —
F Tax withholding on vested shares 160 $142.77 $22.8K
M Option exercise derivative · Restricted Stock Units 774 — —
M Option exercise derivative · Restricted Stock Units 329 — —
Filing: Form 4 (Insider Transaction) Insider: Mock James M (Chief Financial Officer) Shares: 1,638
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

MRNA insider Bancel Stephane (Director, Chief Executive Officer) sold 499,246 shares (~$28.72M)

Bancel Stephane, listed as Director, Chief Executive Officer at Moderna, Inc., reported an open-market sale of 499,246 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 499,246 $19.15 $9.56M
S Open-market sale 147,473 $56.21 $8.29M
S Open-market sale 124,838 $56.96 $7.11M
S Open-market sale 39,891 $58.12 $2.32M
S Open-market sale 187,044 $58.79 $11.00M
M Option exercise 252,469 $19.15 $4.83M
M Option exercise derivative · Stock Option (Right to Buy) 370,853 — —
M Option exercise derivative · Stock Option (Right to Buy) 128,393 — —
M Option exercise derivative · Stock Option (Right to Buy) 187,541 — —
M Option exercise derivative · Stock Option (Right to Buy) 64,928 — —
Filing: Form 4 (Insider Transaction) Insider: Bancel Stephane (Director, Chief Executive Officer) Shares: 499,246 Est. Value: $28.72M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Moderna, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-09-15

MRNA Form 144 filed for proposed insider sale by Hoge Stephen (40,281 shares) ~$5.88M

Hoge Stephen filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Hoge Stephen Shares: 40,281 Est. Value: $5.88M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-09-14

MRNA Form 144 filed for proposed insider sale by Hoge Stephen (40,294 shares) ~$5.81M

Hoge Stephen filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Hoge Stephen Shares: 40,294 Est. Value: $5.81M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-10

MRNA Form 144 filed for proposed insider sale by Mock James M (34,836 shares) ~$4.69M

Mock James M filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Mock James M Shares: 34,836 Est. Value: $4.69M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-01

MRNA Form 144 filed for proposed insider sale by Klinger Shannon Thyme (3,471 shares) ~$485.8K

Klinger Shannon Thyme filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Klinger Shannon Thyme Shares: 3,471 Est. Value: $485.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-05

MRNA Form 144 filed for proposed insider sale by Bancel Stephane (499,246 shares) ~$28.96M

Bancel Stephane filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Bancel Stephane Shares: 499,246 Est. Value: $28.96M
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Moderna, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-30

MRNA filed 8-K — material company event

Moderna, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-01

MRNA filed 8-K — material company event

Moderna, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-31

MRNA filed 8-K — material company event

Moderna, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Moderna, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-31

MRNA filed Quarterly Report (10-Q)

Moderna, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Moderna, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MRNA. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MRNA SEC Filings

What SEC filings does Moderna, Inc. submit to the SEC?

Moderna, Inc. (MRNA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about MRNA?

A Form 4 for MRNA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Moderna, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for MRNA?

The 10-K is Moderna, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all MRNA SEC filings directly on EDGAR?

You can view all historical Moderna, Inc. filings on the SEC EDGAR company page for MRNA. Each filing card on this page links directly to the original SEC document.

How often does Moderna, Inc. file with the SEC?

Moderna, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling MRNA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for MRNA

MRNA Full Stock Analysis MRNA Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MRNA analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MRNA stock analysis page.

MRNA Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer